mai-2
APLICATIONS
New Drug Approval | USFDA Approves Vyvgart Hytrulo for Subcutaneous Use...
VYVGART® Hytrulo is the first FDA-approved subcutaneous (SC) injectable for generalized myasthenia gravis (gMG)
SAN DIEGO, June 20, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme")...
